FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
This article was originally published in The Gray Sheet
Executive Summary
Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage